At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 92 enrolled
Drug / intervention
MOR00208 (formerly Xmab 5574)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa, Open-label, Multicenter Study of Single-agent MOR00208, an Fc-optimized Anti-CD19 Antibody, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
In Brief
A Phase 2 clinical trial evaluating MOR00208 (formerly Xmab 5574) for Non-Hodgkin Lymphoma. Completed, enrolled 92 participants across 22 sites in 7 countries.
Detailed Summary
This is an open-label, multicenter study to characterize the safety and efficacy of the human anti-CD19 antibody MOR00208 in adult patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) who have received at least 1 prior therapy containing rituximab (at least once).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin Lymphoma
CountriesBelgium, Germany, Hungary, Italy, Poland, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartApr 2013
Primary CompletionApr 2022
TodayJul 2026
First PostedSep 13, 2012
Enrollment StartApr 23, 2013
Primary CompletionApr 6, 2022
TodayJul 2, 2026
Enrollment to primary: 9.0 yearsPosted 13.8 years ago
Interventions
MOR00208 (formerly Xmab 5574)drug